1. Home
  2. JBDI vs INTS Comparison

JBDI vs INTS Comparison

Compare JBDI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBDI Holdings Limited Ordinary Shares

JBDI

JBDI Holdings Limited Ordinary Shares

N/A

Current Price

$1.38

Market Cap

12.7M

Sector

N/A

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.75

Market Cap

11.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBDI
INTS
Founded
1983
2012
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.7M
11.4M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
JBDI
INTS
Price
$1.38
$4.75
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
39.3K
27.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.22
52 Week High
$2.28
$8.06

Technical Indicators

Market Signals
Indicator
JBDI
INTS
Relative Strength Index (RSI) 56.47 63.57
Support Level $1.13 $4.50
Resistance Level $1.41 $5.00
Average True Range (ATR) 0.12 0.29
MACD -0.01 0.09
Stochastic Oscillator 72.73 90.09

Price Performance

Historical Comparison
JBDI
INTS

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: